Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claims 1-42 (Cancelled).

Claim 43 (New): A compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof:

$$R^{1} \xrightarrow{X} \begin{array}{c} H \\ N \\ N - N \end{array} \qquad R^{2}$$

Formula (I)

wherein:

X is S:

R¹ is optionally substituted furan-C₁alkyl;

R² is optionally substituted Ar-C₀₋₆alkyl; and

 R^3 is H, optionally substituted $C_{1\text{-}6}$ alkyl, $C_{3\text{-}6}$ alkenyl, or $C_{3\text{-}6}$ alkynyl.

Claim 44 (New): The compound according to claim 43, selected from:

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-phenylamino-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

5-(5-p-tolyl amino-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-p-tolyl amino-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

5-(5-o-tolyl amino-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-o-tolyl amino-4H-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-(2-methyl-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole;

3-(2-methoxy-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;

5-(5-(2-methoxyphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester

3-(2-methoxy-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole;

5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-(3-methylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-(4-fluoro-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;

5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-(4-fluorophenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde; and 3-(4-fluoro-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole or a pharmaceutically acceptable salt or solvate thereof.

Claim 45 (New): The compound according to claim 43, selected from:

3-anilino-5-(furan-3-ylmethylthio)-1,2,4-triazole;

3-anilino-5-(furan-2-ylmethylthio)-1,2,4-triazole;

3-(2-methyl-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;

3-(3-methyl-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;

3-(3-methyl-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole; and

or a pharmaceutically acceptable salt or solvate thereof.

Claim 46 (New): The compound according to claim 43, selected from:

3-(2-isopropyl-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;

5-(5-(2-isopropylphenylamino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carboxylic acid ethyl ester;

5-(5-(2-isopropyl amino)-4*H*-[1,2,4]triazol-3-ylsulfanylmethyl)-furan-2-carbaldehyde;

3-(2-isopropyl-anilino)-5-(furan-3-ylmethylthio)-1,2,4-triazole;

3-(4-methyl-anilino)-5-(furan-2-ylmethylthio)-1,2,4-triazole;

 $3\hbox{-}(4\hbox{-methyl-anilino})\hbox{-}5\hbox{-}(furan\hbox{-}3\hbox{-}ylmethylthio})\hbox{-}1,2,4\hbox{-triazole};$

or a pharmaceutically acceptable salt or solvate thereof.

Claim 47 (New): A pharmaceutical composition comprising the compound according to claim 43 and a pharmaceutically acceptable carrier.

Claim 48 (New): A pharmaceutical composition comprising the compound according to claim 44 and a pharmaceutically acceptable carrier.

Claim 49 (New): A pharmaceutical composition comprising the compound according to claim 45 and a pharmaceutically acceptable carrier.

Claim 50 (New): A pharmaceutical composition comprising the compound according to claim 46 and a pharmaceutically acceptable carrier.

Claim 51 (New): A method of making the compound of Formula (I) according to claim 43, wherein X is sulfur, comprising the steps of:

a) combining an isothiocyanate of Formula (II):

with thiourea to provide a compound of Formula (III):

b) treating the compound of Formula (III) with an alkyl halide under basic conditions to provide a compound of Formula (IV):

c) treating the compound of formula (IV) with hydrazine to provide a compound of Formula (V):

HS
$$N$$
 NHR² Formula (V)

d) treating the compound of formula (V) with an alkyl halide under basic conditions to provide a compound of Formula (VI):

e) protecting the compound of formula (VI) to provide a compound of Formula (VII):

f) alkylating the compound of formula (VII) with an alkyl halide to provide a compound of Formula (VIII):

$$R^1S$$
 N
 N
 R^3

Formula (VIII)

g) deprotecting the compound of formula (VIII) to provide the compound of Formula (I).

Claim 52 (New): A method of inhibiting MetAP2, comprising contacting MetAP2 with the compound of Formula (IA) according to claim 43 or a pharmaceutically acceptable salt or solvate thereof.